LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Streck Enters into Distribution Agreement with HiSS Diagnostics

By LabMedica International staff writers
Posted on 09 Feb 2017
Print article
Streck, Inc., which develops and manufactures products for clinical and research laboratories, has entered into a distribution agreement for its molecular and cell stabilization products with HiSS Diagnostics GmbH, a distributor of medical laboratory products.

Streck offers automated erythrocyte sedimentation rate instruments, kits and reagents, and blood collection tubes for sample collection, stabilization and transportation. Its product portfolio also includes flow cytometry, body fluids and urinalysis instruments, as well as molecular diagnostic instruments and consumables.

Streck’s cell stabilization products include Cell-Free DNA Urine Preserve, a formaldehyde-free liquid reagent that stabilizes cell-free DNA (cfDNA) in urine; Cell-Free DNA BCT CE, a direct-draw blood collection tube which stabilizes nucleated blood cells and prevents the release of genomic DNA, allowing isolation of high-quality cell-free DNA for a wide range of downstream applications commonly used in clinical research studies, drug discovery and diagnostic assay development; and Cell-Free RNA BCT CE, a blood collection tube with a patented preservative which stabilizes circulating RNA in plasma and prevents the release of non-target background RNA from blood cells during sample processing and storage. The company’s molecular product line includes Streck Antibiotic Resistance Monitoring & Detection (ARM-D) kits, PhilisaFAST DNA Polymerase and Streck’s Real-Time PCR System, the Zulu RT.

HiSS Diagnostics sells products for medical microbiology, immunology and quality assurance in the medical laboratory. Its product offerings also include a full range of antibodies for flow cytometry and hematology, research and diagnostics products for next-generation sequencing, microarrays and qPCR in oncology and hematology and other applications, isolation and sequencing of cell-free DNA in liquid biopsy.

“We are pleased to partner with a company that will allow Streck increased market penetration,” said Connie Ryan, President and CEO at Streck. “In addition, HiSS will be able to provide excellent local support to our German customers.”

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more